Account (R)-4-Methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one
- Catalog No. :
- ACJANL745
- CAS No. :
- 1884712-47-3
- Molecular Formula :
- C22H22N6O
- Molecular Weight :
- 386.46
IUPAC Name:(R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one
![(R)-4-Methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one structure diagram](/images/productimg/no-pic.svg)
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$126.00Login to see priceIn stockInquiry
100mg98%$216.00Login to see priceIn stockInquiry
250mg98%$366.00Login to see priceInquiryInquiry
1g98%$1314.00Login to see priceInquiryInquiry
Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.
0 Reviews:View Reviews
Product Information
| Product Name | (R)-4-Methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one |
|---|---|
| IUPAC Name | (R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one |
| Molecular Formula | C22H22N6O |
| Molecular Weight | 386.46 |
| SMILES | O=C1C[C@@H](C)NC2=C(C3=CC4=C(N(C)N=C4C5=CN(C)N=C5)C=C3)C=CC=C2N1 |
| InChI Key | BFTKDWYIRJGJCA-CYBMUJFWSA-N |
| Synonym | CPI-637;CPI 637;CPI637;2H-1,5-Benzodiazepin-2-one, 1,3,4,5-tetrahydro-4-methyl-6-[1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-, (4R)-;CPI-637 >=98% (HPLC);(R)-4-Methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one;Inhibitor,inhibit,HAT,Epigenetic Reader Domain,CPI637,CPI-637,Histone Acetyltransferase,HATs;CPI-637, 10 mM in DMSO;CPI-637/1884712-47-3/98% |
| CAS No. | 1884712-47-3 |
Safety Data
- Pictogram
- Signal Word
- Warning
- Hazard Statement(s)
- H302-H315-H319-H335
- Precautionary Statement(s)
- P261-P305+P351+P338
